Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 8 de 8
Filtrer
1.
Adv Exp Med Biol ; 1150: 11-16, 2019.
Article de Anglais | MEDLINE | ID: mdl-30357709

RÉSUMÉ

Progranulin is a growth and survival factor implicated in tumorigenesis and drug resistance. Several studies showed that progranulin is expressed in breast cancer tissue and inversely correlates with survival. B lymphocyte chemoattractant, also known as B cell-attracting chemokine 1 (BCA-1), is a member of the CXC subtype of the chemokine superfamily. BCA-1 is critical for secondary lymphoid tissue development and navigation of lymphocytes within the microcompartments of the tissue. There are no data on the content of progranulin and BCA-1 in bronchoalveolar lavage fluid (BALF) of non-small cell lung cancer (NSCLC) patients. To study this issue, we measured BALF content of progranulin and BCA-1 in 46 NSCLC patients before chemotherapy and 15 healthy subjects. Both markers were elevated in cancer patients compared to healthy subjects (progranulin: 61.4 (1.6-384.0) vs. 6.5 (0.6-12.9) ng/ml, p = 0.001 and BCA-1: 30.8 (24.3-70.8) vs. 15.4 (13.3-19.5) pg/ml, p = 0.0001). The cut-off BALF level concerning NSCLC vs. controls, investigated using the receiver-operating characteristic (ROC) curve, yielded 6.5 ng/ml for progranulin and 15.4 pg/ml for BCA-1. We failed to find any association between the BALF content of progranulin or BCA-1 and the stage of tumor or prospectively assessed treatment response. However, BALF progranulin associated with time to tumor progression (r = 0.61; p = 0.04). In addition, a higher BALF content of BCA-1 in NSCLC patients associated with shorter overall survival. We conclude that progranulin and BCA-1 in BALF of NSCLC patients before chemotherapy may be prognostic factors of cancer progression.


Sujet(s)
Liquide de lavage bronchoalvéolaire/composition chimique , Carcinome pulmonaire non à petites cellules/métabolisme , Chimiokine CXCL13/analyse , Tumeurs du poumon/métabolisme , Progranulines/analyse , Lymphocytes B , Carcinome pulmonaire non à petites cellules/diagnostic , Carcinome pulmonaire non à petites cellules/mortalité , Études cas-témoins , Chimiokine CXCL13/métabolisme , Chimiokines , Humains , Tumeurs du poumon/diagnostic , Tumeurs du poumon/mortalité , Pronostic , Taux de survie
2.
Adv Exp Med Biol ; 756: 313-9, 2013.
Article de Anglais | MEDLINE | ID: mdl-22836649

RÉSUMÉ

Angiogenesis plays important role in tumor growth and development. Protein ligands and their receptor tyrosine kinases are crucial in tumor related angiogenesis. Ligand/receptor systems such as vascular endothelial growth factor (VEGF), and tyrosine kinase with immunoglobulin-like and epidermal growth factor homology domains (Tie) family play important role in this phenomenon. The aim of this study was to evaluate the concentration of soluble receptor of VEGF (sVEGF R1) and Tie-2 domain in plasma of lung cancer patients before and after chemotherapy. Forty four lung cancer patients, 11 with small lung cancer (SCLC), 5 females and 6 males (mean age 60.2, range 39-72 years), and 33 patients with non-small cell lung cancer (N-SCLC), 6 females and 27 males (mean age 61.9, range 42-78 years) received four courses of chemotherapy. Control group consisted of 44 patients with COPD, 4 females and 40 males (mean age 37.1, 18-60 years). In all cases clinical partial response was achieved. Both sVEGF R1 and Tie-2 concentrations were elevated in cancer group before treatment compared with control: sVEGF (pg/ml): 60.7 and 66.2 vs. 48.8 and Tie-2 (ng/ml): 37.3 and 37.5 vs. 30.7 in SCLC and N-SCLC vs. C, respectively. Treatment decreased sVEGF R1 (pg/ml): 66.7 vs. 11.6 (p < 0.05) and 66.2 vs. 14.39 (p < 0.001), and Tie-2 (ng/ml): 37.3 vs. 26.3 (p < 0.05) and 37.5 vs. 25.7 (p < 0.001) in SCLC and N-SCLC, respectively. We conclude that VEGF R1and Tie-2 receptors may play important role in lung cancer development and their receptor concentrations may reflect the patients' response to treatment.


Sujet(s)
Protocoles de polychimiothérapie antinéoplasique/usage thérapeutique , Tumeurs du poumon/sang , Tumeurs du poumon/traitement médicamenteux , Récepteur TIE-2/sang , Récepteur-1 au facteur croissance endothéliale vasculaire/sang , Adulte , Sujet âgé , Marqueurs biologiques tumoraux , Cisplatine/usage thérapeutique , Désoxycytidine/analogues et dérivés , Désoxycytidine/usage thérapeutique , Étoposide/usage thérapeutique , Femelle , Humains , Mâle , Adulte d'âge moyen , Néovascularisation pathologique , Broncho-pneumopathie chronique obstructive/sang , Résultat thérapeutique ,
3.
Eur J Med Res ; 15 Suppl 2: 95-7, 2010 Nov 04.
Article de Anglais | MEDLINE | ID: mdl-21147631

RÉSUMÉ

A twenty eight-year-old male presented with a two week history of dyspnea, cough, hemoptysis, chest pain, and fever 38-39°C. He also complained of loss of appetite, general weakness and left leg pain for two months preceding admission. He was referred with suspicion of lung tumor to our institution. Chest X-ray showed almost total atelectasis of the right lung with compensatory overinflation of the contralateral lung. Using computed tomography (CT), a lesion of diameter of 19.3 x 14.1 x 19.1 cm in the right lung, pleuritis, Th3 osteolysis, and compensatory overinflation of the left lung was seen. Bronchoscopy revealed a total obstruction of the right main bronchus due to submucosal infiltration and compression of the right main bronchus with negative histology of bronchial biopsy specimens. Transthoracic fine needle aspiration revealed celullae suspectae probabiliter neoplasmaticae suggesting tumor fusocellularis. USG of the abdomen revealed liver with numerous heterogeneous, solid areas hypo- and hyperechogenic, some of them with features of liquid or the disintegration up to diameter of 74 mm. Subsequent fine needle aspirations of the thorax and liver revealed fibrolamellar hepatocarcinoma and carcinoma adenoides of the lung. Patient underwent chemotherapy with 5-FU/DDP/VCR with no response. This report presents a case of a rare lung metastasis from FL-HCC.


Sujet(s)
Tumeurs du foie/anatomopathologie , Tumeurs du poumon/secondaire , Adulte , Ponction-biopsie à l'aiguille , Carcinome hépatocellulaire/anatomopathologie , Humains , Mâle
4.
Exp Oncol ; 26(4): 316-9, 2004 Dec.
Article de Anglais | MEDLINE | ID: mdl-15627066

RÉSUMÉ

UNLABELLED: The AIM of this study was to assess the influence of chemotherapy on the serum levels of IGF-I and IGF-II in patients with lung cancer. METHODS: The study included 38 patients (33 males and 5 females) at mean age of 59.8, diagnosed histologically with lung cancer. Twenty five patients had non-small cell lung cancer (NSCLC) including 11 patients with squamous cell carcinoma (SCC), 5 patients with adenocarcinoma and 9 patients without an essential histological type of NSCLC. A total of 13 patients had small cell lung cancer (SCLC). The control group consisted of 10 healthy volunteers. The peripheral blood samples were taken before and after 4 cycles of chemotherapy. IGF-I and IGF-II levels were assessed by ELISA method. RESULTS: Serum levels of IGF-I and IGF-II measured before chemotherapy were significantly higher in both NSCLC and SCLC groups in comparison with controls. There were no significant differences of serum levels of both growth factors before and after 4 cycles of chemotherapy. Serum levels of IGF-I and IGF-II were still high after chemotherapy in patients with NSCLC and SCLC. Patients with SCC and adenocarcinoma had similar serum levels of IGF-I and IGF-II without statistical differences. CONCLUSION: Serum levels of IGF-I and IGF-II were significantly higher in patients with NSCLC and SCLC before chemotherapy than in controls. Chemotherapy had no influence on the serum levels of insulin-like growth factors (IGFs). Serum levels of IGF-I and IGF-II did not depend on a histological type of NSCLC either.


Sujet(s)
Protocoles de polychimiothérapie antinéoplasique/usage thérapeutique , Marqueurs biologiques tumoraux/sang , Carcinome pulmonaire non à petites cellules/traitement médicamenteux , Carcinome pulmonaire non à petites cellules/anatomopathologie , Carcinome à petites cellules/traitement médicamenteux , Carcinome à petites cellules/anatomopathologie , Facteur de croissance IGF-II/analyse , Facteur de croissance IGF-I/analyse , Tumeurs du poumon/traitement médicamenteux , Tumeurs du poumon/anatomopathologie , Détermination du point final , Femelle , Humains , Mâle , Adulte d'âge moyen , Stadification tumorale , Résultat thérapeutique
5.
Rocz Akad Med Bialymst ; 49: 246-51, 2004.
Article de Anglais | MEDLINE | ID: mdl-15631351

RÉSUMÉ

PURPOSE: We evaluated the clinical usefulness of interleukin-18 (IL-18) and soluble interleukin-2 receptor (sIL-2R) during chemotherapy of lung cancer in relation to the histological type of the tumor, clinical stage, response to therapy and time survival. MATERIAL AND METHODS: Serum levels of IL-18 and sIL-2R were determined in 73 patients (62 males; mean age 64 years; 41 with non-small cell lung cancer-NSCLC, 32 with small cell lung cancer-SCLC); 12 healthy subjects served as controls. To determine IL-18 serum concentrations (Elisa), venous blood samples were collected from each patient before and after chemotherapy. RESULTS: The mean serum IL-18 level in all patients with lung cancer was significantly higher compared with healthy volunteers (p = 0.0001; NSCLC vs control p = 0.0001; SCLC vs control p = 0.004). In NSCLC group with stage IV the mean IL-18 level was significantly higher than those with stage IIIB (p = 0.04). Regarding tumor stage and response to therapy, no significant differences in IL-18 were observed. Using cut-off serum IL-18 concentration of 319.6 pg/ml, the prognoses of the two groups were different, but it was not statistically significant. The serum levels of sIL-2R in NSCLC patients were significantly higher than in controls (p = 0.018). There were no significant differences in serum sIL-2R levels in relation to clinical stage of lung cancer and response to therapy. The cut-off value between high and low serum sIL-2R concentration was defined as 582.27 U/ml. The difference in survival rate between the high and low sIL-2R groups was not significant. CONCLUSIONS: Serum IL-18 and sIL-2R levels can be useful in clinical practice, but their practical significance needs further studies.


Sujet(s)
Marqueurs biologiques tumoraux/sang , Carcinome pulmonaire non à petites cellules/sang , Carcinome à petites cellules/sang , Interleukine-18/sang , Tumeurs du poumon/sang , Récepteurs à l'interleukine-2/sang , Antinéoplasiques/usage thérapeutique , Carcinome pulmonaire non à petites cellules/traitement médicamenteux , Carcinome à petites cellules/traitement médicamenteux , Études cas-témoins , Femelle , Humains , Tumeurs du poumon/traitement médicamenteux , Tumeurs du poumon/anatomopathologie , Mâle , Adulte d'âge moyen , Stadification tumorale
6.
Pneumonol Alergol Pol ; 69(11-12): 669-72, 2001.
Article de Polonais | MEDLINE | ID: mdl-12134444

RÉSUMÉ

We describe a 26 year old woman treated for near a year because of deafness, purulent otitis, cough and purulent skin lesions. She was treated by otolaryngologist. Sputum examination for acid fast bacilli and chest x-ray were not done a that time. In hospital chest x-ray revealed a cava in left lung and tuberculous bacilli were found in sputum and in content from ear. Tuberculin test was positive. Tuberculosis of lung, skin and cor was recognized. After 4 months of initial treatment patient was referred to outpatient department for further therapy.


Sujet(s)
Otite moyenne sécrétoire/diagnostic , Otite moyenne sécrétoire/microbiologie , Tuberculose cutanée/diagnostic , Tuberculose/diagnostic , Adulte , Antituberculeux/usage thérapeutique , Femelle , Perte d'audition/microbiologie , Humains , Otite moyenne sécrétoire/traitement médicamenteux , Expectoration/microbiologie , Facteurs temps , Résultat thérapeutique , Tuberculose/complications , Tuberculose/traitement médicamenteux , Tuberculose cutanée/complications , Tuberculose cutanée/traitement médicamenteux
7.
Pneumonol Alergol Pol ; 69(11-12): 673-6, 2001.
Article de Polonais | MEDLINE | ID: mdl-12134445

RÉSUMÉ

We describe a 75 year old patient treated because of arthrosis and recurrent pneumonia for a year. In hospital acid-fast bacilli were found in sputum. Chest x-ray revealed massive inflammatory and fibrous lesions. Pelvis x-ray revealed lesions estimated as tuberculosis. Tuberculosis of lungs and pelvis bones was recognised. After 3 months of antituberculous treatment patient was referred to outpatient department for further therapy.


Sujet(s)
Antituberculeux/usage thérapeutique , Os coxal/microbiologie , Tuberculose ostéoarticulaire/imagerie diagnostique , Tuberculose ostéoarticulaire/traitement médicamenteux , Tuberculose pulmonaire/imagerie diagnostique , Tuberculose pulmonaire/traitement médicamenteux , Sujet âgé , Humains , Mâle , Mycobacterium tuberculosis/effets des médicaments et des substances chimiques , Mycobacterium tuberculosis/isolement et purification , Radiographie , Expectoration/microbiologie , Facteurs temps , Résultat thérapeutique
8.
Pneumonol Alergol Pol ; 67(9-10): 477-80, 1999.
Article de Polonais | MEDLINE | ID: mdl-10808392

RÉSUMÉ

A case of coexisting tongue and pulmonary tuberculosis is presented. A 55 year old man, farmer, an alcohol abuser, suffered from respiratory symptoms infection was admitted to Dental Surgery Department because of carcinoma of tongue suspicion. His tongue was oedematous, stiff with numerous painful ulcerations. Thin-needle biopsy of the tongue revealed granuloma typical for tuberculosis. Chest x-ray examination revealed disseminated lesions and cavernous infiltration in the lungs. Tuberculosis of lungs and tongue was recognised. Antimycobacterial treatment was introduced. 2 weeks later, tuberculous bacilli were cultured. Excellent clinical and mainly-local (tongue) improvement has been achieved.


Sujet(s)
Maladies de la langue/diagnostic , Tuberculose de la cavité buccale/diagnostic , Tuberculose pulmonaire/diagnostic , Biopsie , Diagnostic différentiel , Humains , Mâle , Adulte d'âge moyen , Tumeurs de la langue/diagnostic
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE